ArriVent BioPharma Cash Flow Statement (2023-2026) | AVBP

1Y3Y5Y7Y10YAll
Download Data
Cash Flow Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter) -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M
Share-based Compensation (Quarter) 0.17M193.00M216.00M0.32M0.62M0.77M0.86M0.95M2.27M3.31M3.72M3.22M5.49M
Gains from Investment Securities (Quarter) 0.80M3.94M1.02M1.12M2.53M4.06M1.88M2.01M4.33M7.22M
Non-cash Items (Quarter) 32.96M0.65M0.63M0.72M1.02M1.20M28.48M31.68M1.99M
Cash from Operations (Quarter) -16.88M-8.61M-15.44M-14.91M-18.63M-19.09M-16.34M-16.15M-68.01M-26.12M-35.80M-30.66M-41.89M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) (Quarter) -0.56M
Change in Working Capital
Change in Account Payables (Quarter) -0.38M3.69M-2.23M0.29M-0.37M-0.35M0.83M-0.86M0.58M-0.30M1.87M-0.01M2.81M
Change in Accured Expenses (Quarter) -2.04M3.18M-1.22M1.64M-0.96M2.14M2.23M2.97M-4.88M7.03M0.09M4.43M-3.83M
Investing Activities
Change in Acquisitions & Divestments (Quarter) 46.64M35.48M39.61M79.98M67.97M
Cash from Investing Activities (Quarter) 36.82M13.91M-50.76M-71.20M3.58M
Financing Activities
Other financing activities (Quarter) 1.34M0.05M0.30M-0.30M0.02M
Change in Capital Stock
Shares Issued (Quarter) 0.03M0.00M0.04M0.28M0.00M0.04M185.91M6.52M-6.15M0.05M0.08M54.72M
Preferred Shares Issued (Quarter) 44.94M-0.02M
Misc.
Cash from Financing Activities (Quarter) 44.97M-0.02M-1.03M-1.06M185.63M0.36M0.53M0.06M6.76M75.11M86.47M34.73M54.87M
Change in Cash (Quarter) 28.09M-33.63M-16.48M9.03M167.00M-18.72M-15.81M-208.56M-24.43M62.90M-0.09M-67.13M16.56M
Free Cash Flow (Quarter) -16.88M-8.61M-15.44M-14.91M-18.63M-19.09M-16.34M-16.15M-68.01M-26.12M-35.80M-30.66M-41.89M
Net Cash Flow (Quarter) 28.09M-8.63M-16.48M-15.97M167.00M-18.72M-15.81M-16.10M-24.43M62.90M-0.09M-67.13M16.56M